IQVIA艾昆纬：2024年MASH临床研究见解-GLP-1激动剂的可及性增加白皮书（英文版）

Metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) are growing public health concerns characterized by liver steatosis (fat build-up), inflammation and fibrosis due to metabolic dysfunction. Around one-fifth of MASLD patients have MASH, a major cause of liver fibrosis and cirrhosis. Clinical development in MASH faces challenges, with an 83% decrease in median recruitment rates for Phase IIb and III clinical trials in the U